| Literature DB >> 26248153 |
Michael J Reiter1, Justin E Costello, Ryan B Schwope, Christopher J Lisanti, Michael B Osswald.
Abstract
Serum tumor markers are firmly entrenched as one of the primary tools in an oncologist's armamentarium. They can be implemented in a broad range of applications from diagnostic assistance, assessing prognosis, or guiding therapeutic decisions. However, tumor markers also have limitations, which significantly impact how they should be used. Radiologists should be familiar with the following most prevalent tumor markers, which will all be discussed here: prostate-specific antigen (prostate), carcinoembryonic antigen (colon), α-fetoprotein (hepatocellular and testicular), carbohydrate antigen 19.9 (pancreas), cancer antigen 125 (ovarian), human chorionic gonadotropin/lactic dehydrogenase (testicular), and chromogranin A (neuroendocrine). This knowledge should avoid needless intervention, enhance image interpretation, and ultimately provide optimal patient care.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26248153 DOI: 10.1097/RCT.0000000000000297
Source DB: PubMed Journal: J Comput Assist Tomogr ISSN: 0363-8715 Impact factor: 1.826